The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Amelioration of amyloid β‐FcγRIIb neurotoxicity and tau pathologies by targeting LYN
Abstract
SRC‐family kinases (SFKs) have been implicated in Alzheimer's disease (AD), but their mode of action was scarcely understood. Here, we show that LYN plays an essential role in amyloid β (Aβ)‐triggered neurotoxicity and tau hyperphosphorylation by phosphorylating Fcγ receptor IIb2 (FcγRIIb2). We found that enzyme activity of LYN was increased in the brain of AD patients and was promoted in neuronal cells exposed to Aβ 1–42 (Aβ 1–42 ). Knockdown of LYN expression inhibited Aβ 1–42 ‐induced neuronal cell death. Of note, LYN interacted with FcγRIIb2 upon exposure to Aβ 1–42 and phosphorylated FcγRIIb2 at Tyr273 within immunoreceptor tyrosine‐based inhibitory motif in neuronal cells. With the use of the structure‐based drug design, we isolated KICG2576, an ATP‐competitive inhibitor of LYN. Determination of cocrystal structure illustrated that KICG2576 bound to the cleft in the LYN kinase domain and inhibited LYN with a half‐maximal inhibitory concentration value of 0.15 µM. KICG2576 inhibited Aβ‐ or FcγRIIb2‐induced cell death, and this effect was better than pyrazolopyrimidine 1, a widely used inhibitor of SFK. Upon exposure to Aβ, KICG2576 blocked the phosphorylation of FcγRIIb2 and translocation of phosphatidylinositol 3,4,5‐trisphosphate 5‐phosphatase 2, a binding protein to the phosphorylated FcγRIIb2, to the plasma membrane, resulting in the inhibition of tau hyperphosphorylation, the downstream event of Aβ 1–42 ‐FcγRIIb2 binding. Furthermore, intracerebroventricular injection of KICG2576 into mice ameliorated Aβ‐induced memory impairment. These results suggest that LYN plays a crucial role in Aβ 1–42 ‐mediated neurotoxicity and tau pathology, providing a therapeutic potential of LYN in AD.—Gwon, Y., Kim, S.‐H., Kim, H. T., Kam, T.‐I., Park, J., Lim, B., Cha, H., Chang, H.‐J., Hong, Y. R., Jung, Y.‐K. Amelioration of amyloid β‐FcγRIIb neurotoxicity and tau pathologies by targeting LYN. FASEB J. 33, 4300–4313 (2019). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Amongst these AD-specific targets were genes like PTBP2, a previously identified miR-132 target implicated in Tau mRNA splicing [85], LYN, a kinase shown to play a role in amyloid-β-triggered neurotoxicity and TAU hyperphosphorylation [86], and NFE2L2, ZEB2, SPRED1 and RASA1, all previously shown to be regulated by miR-132 [87–89] (Fig. 5F).”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [86]
In the citing paper
“Amongst these AD-specific targets were genes like PTBP2, a previously identified miR-132 target implicated in Tau mRNA splicing [85], LYN, a kinase shown to play a role in amyloid-β-triggered neurotoxicity and TAU hyperphosphorylation [86], and NFE2L2, ZEB2, SPRED1 and RASA1, all previously shown to be regulated by miR-132 [87–89] (Fig. 5F).”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [86]
Citations
Cites
Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1836 · Cited by 1,513
Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer’s disease
Kam, T.-I., Song, S., Gwon, Y., Park, H., Yan, J.-J., Im, I., Choi, J.-W., Choi, T.-Y., Kim, J., Song, D.-K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66827 · Cited by 128
Self-citation
Flagged first, then by citations
Research works printed but not linked: 46
- 10.1016/j.tips.2011.11.002 · DOI
- 10.1016/j.tins.2011.09.005 · DOI
- 10.1242/dev.132456 · DOI
- 10.1038/srep40912 · DOI
- 10.1016/j.biopsych.2017.06.004 · DOI · Paper page
- 10.1038/nn.3178 · DOI
- 10.1016/S0306-4522(03)00025-3 · DOI
- 10.1523/JNEUROSCI.1858-12.2012 · DOI
- 10.1038/nrrheum.2016.131 · DOI
- 10.1111/j.1600-065X.2008.00758.x · DOI
- 10.1186/1742-2094-9-117 · DOI
- 10.7554/eLife.18691 · DOI
- Gwon Y., 2018, TOM1 regulates neuronal accumulation of amyloid-β oligomers by FcγRIIb2 variant in Alzheimer's disease, J. Neurosci., 38, 9001, 10.1523/JNEUROSCI.1996-17.2018 · DOI
- 10.1093/hmg/dds100 · DOI
- 10.1038/cdd.2011.209 · DOI
- 10.1074/jbc.M211402200 · DOI
- 10.1016/S0076-6879(97)76066-X · DOI · Paper page
- 10.1107/S0907444996012255 · DOI
- 10.1107/S0907444904019158 · DOI · Paper page
- 10.1107/S0907444909042073 · DOI · Paper page
- 10.1016/j.cellsig.2008.07.004 · DOI
- 10.1371/journal.pone.0084746 · DOI
- Freedman T. S., 2015, LynA regulates an inflammation-sensitive signaling checkpoint in macrophages, Elife, 4, e09183, 10.7554/eLife.09183 · DOI
- 10.4049/jimmunol.1202401 · DOI · Paper page
- 10.1083/jcb.200711066 · DOI
- 10.1074/jbc.M114.567321 · DOI
- 10.1021/bi972029u · DOI
- 10.1126/science.1862342 · DOI
- 10.1002/jcp.22946 · DOI
- 10.1038/srep40753 · DOI
- 10.1093/brain/awx132 · DOI
- 10.1093/brain/awn125 · DOI
- 10.1016/j.neurobiolaging.2011.10.027 · DOI
- 10.1002/emmm.201302771 · DOI
- Dallari S., 2017, Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses, Nat. Commun., 8, 14830, 10.1038/ncomms14830 · DOI
- 10.1084/jem.20040382 · DOI
- 10.3109/10428194.2014.907897 · DOI
- 10.1111/j.1471-4159.2005.03397.x · DOI
- Hernandez-Rapp J., 2014, A PrP(C)-caveolin-Lyn complex negatively controls neuronal GSK3β and serotonin 1B receptor, Sci. Rep., 4, 4881, 10.1038/srep04881 · DOI
- 10.3389/fcell.2014.00063 · DOI
- 10.1007/s00018-014-1706-0 · DOI
- 10.1371/journal.pone.0132604 · DOI
- 10.1074/jbc.M600627200 · DOI
- 10.1038/ng.2802 · DOI · Paper page
- 10.1158/1535-7163.MCT-05-0171 · DOI
- 10.1042/BJ20070797 · DOI
Cited by
Sorted by citations
Penning, A., Snoeck, S., Ormaechea, O. R., Ayyildiz, D., Polzer, O., Buitrago-Arango, M., Capobianco, R., de Winter, F., Balusu, S., Verhaagen, J., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02228-8 · Cited by 6
Metadata
- Authors
- Gwon, Y., Kim, S.-H., Kim, H. T., Kam, T.-I., Park, J., Lim, B., Cha, H., Chang, H.-J., Hong, Y. R., & Jung, Y.-K.
- Affiliations
- School of Biological Sciences Seoul National University Seoul South Korea
- Crystalgenomics Incorporated Gyeonggi-do South Korea
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2018-12-12
- Volume
- 33
- Issue
- 3
- Pages
- 4300-4313
- ISSN
- 0892-6638
- 1530-6860
- Cited by
- 20
- References
- 4
- Language
- en
- Funders
- Cancer Research Institute (NRF-2016R1A2A1A05005304)
- National Research Foundation (NRF-2017M3A9G7073521)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review